[go: up one dir, main page]

WO2016184577A3 - Dry powder composition comprising long-chain rna - Google Patents

Dry powder composition comprising long-chain rna Download PDF

Info

Publication number
WO2016184577A3
WO2016184577A3 PCT/EP2016/000846 EP2016000846W WO2016184577A3 WO 2016184577 A3 WO2016184577 A3 WO 2016184577A3 EP 2016000846 W EP2016000846 W EP 2016000846W WO 2016184577 A3 WO2016184577 A3 WO 2016184577A3
Authority
WO
WIPO (PCT)
Prior art keywords
long
dry powder
powder composition
chain rna
rna molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2016/000846
Other languages
French (fr)
Other versions
WO2016184577A2 (en
Inventor
Benyamin YAZDAN PANAH
Fabian Johannes EBER
Stefanie SEWING
Thomas Ketterer
Thorsten Mutzke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Curevac SE
Original Assignee
Curevac AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curevac AG filed Critical Curevac AG
Priority to EP16728216.9A priority Critical patent/EP3298143A2/en
Publication of WO2016184577A2 publication Critical patent/WO2016184577A2/en
Publication of WO2016184577A3 publication Critical patent/WO2016184577A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0091—Purification or manufacturing processes for gene therapy compositions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Manufacturing & Machinery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention is directed to a storage-stable formulation of long-chain RNA. In particular, the invention concerns a dry powder composition comprising a long-chain RNA molecule. The present invention is furthermore directed to methods for preparing a dry powder composition comprising a long-chain RNA molecule by spray-drying or spray- freeze-drying. The invention further concerns the use of such a dry powder composition comprising a long-chain RNA molecule in the preparation of pharmaceutical compositions and vaccines, to a method of treating or preventing a disorder or a disease, to first and second medical uses of such a dry powder composition comprising a long-chain RNA molecule and to kits, particularly to kits of parts, comprising such a dry powder composition comprising a long-chain RNA molecule.
PCT/EP2016/000846 2015-05-20 2016-05-20 Dry powder composition comprising long-chain rna Ceased WO2016184577A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP16728216.9A EP3298143A2 (en) 2015-05-20 2016-05-20 Dry powder composition comprising long-chain rna

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15001517.0 2015-05-20
EP15001517 2015-05-20

Publications (2)

Publication Number Publication Date
WO2016184577A2 WO2016184577A2 (en) 2016-11-24
WO2016184577A3 true WO2016184577A3 (en) 2017-01-12

Family

ID=53275951

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2016/000846 Ceased WO2016184577A2 (en) 2015-05-20 2016-05-20 Dry powder composition comprising long-chain rna

Country Status (2)

Country Link
EP (1) EP3298143A2 (en)
WO (1) WO2016184577A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3198966A1 (en) 2011-06-08 2012-12-13 Translate Bio, Inc. Cleavable lipids
EP3452101A2 (en) 2016-05-04 2019-03-13 CureVac AG Rna encoding a therapeutic protein
EP4477662A3 (en) 2016-05-04 2025-03-19 CureVac SE Nucleic acid molecules and uses thereof
EP3558356A2 (en) 2016-12-23 2019-10-30 CureVac AG Mers coronavirus vaccine
EP3558354A1 (en) 2016-12-23 2019-10-30 CureVac AG Lassa virus vaccine
WO2019122371A1 (en) 2017-12-21 2019-06-27 Curevac Ag Linear double stranded dna coupled to a single support or a tag and methods for producing said linear double stranded dna

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070172430A1 (en) * 2006-01-20 2007-07-26 Nastech Pharmaceutical Company Inc. Dry powder compositions for rna influenza therapeutics
WO2011069529A1 (en) * 2009-12-09 2011-06-16 Curevac Gmbh Mannose-containing solution for lyophilization, transfection and/or injection of nucleic acids
WO2011069528A1 (en) * 2009-12-09 2011-06-16 Curevac Gmbh Lyophilization of nucleic acids in lactate-containing solutions

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002302814A1 (en) * 2001-06-08 2002-12-23 Powderject Vaccines, Inc. Spray freeze-dried compositions

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070172430A1 (en) * 2006-01-20 2007-07-26 Nastech Pharmaceutical Company Inc. Dry powder compositions for rna influenza therapeutics
WO2011069529A1 (en) * 2009-12-09 2011-06-16 Curevac Gmbh Mannose-containing solution for lyophilization, transfection and/or injection of nucleic acids
WO2011069528A1 (en) * 2009-12-09 2011-06-16 Curevac Gmbh Lyophilization of nucleic acids in lactate-containing solutions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JENSEN D M K ET AL: "Spray drying of siRNA-containing PLGA nanoparticles intended for inhalation", JOURNAL OF CONTROLLED RELEASE, ELSEVIER, AMSTERDAM, NL, vol. 142, no. 1, 25 February 2010 (2010-02-25), pages 138 - 145, XP026892483, ISSN: 0168-3659, [retrieved on 20091022], DOI: 10.1016/J.JCONREL.2009.10.010 *

Also Published As

Publication number Publication date
WO2016184577A2 (en) 2016-11-24
EP3298143A2 (en) 2018-03-28

Similar Documents

Publication Publication Date Title
EP3916091A3 (en) Dry powder composition comprising long-chain rna
WO2016184576A3 (en) Dry powder composition comprising long-chain rna
WO2016184577A3 (en) Dry powder composition comprising long-chain rna
WO2018089851A3 (en) Influenza vaccine
BR112019024747A2 (en) fixed dose formulations
HK1253271A1 (en) Formulations for neoplasia vaccines and methods of preparing them
WO2017070616A3 (en) Sexually transmitted disease vaccines
BR112014004687A2 (en) amino-substituted imidazopyridazine
ZA201900367B (en) Formulation of a peptide vaccine
WO2017070620A3 (en) Broad spectrum influenza virus vaccine
WO2017191258A9 (en) Influenza mrna vaccines
WO2017070626A3 (en) Respiratory virus vaccines
WO2015018380A3 (en) Therapeutic nanoparticles and the preparation methods thereof
BR112013005679A2 (en) substituted imidazopyridazine
EA201691590A1 (en) BENZIMIDAZOL-2-AMINES AS MIDHI INHIBITORS
WO2015160843A8 (en) Ion channel activators and methods of use
ZA202310755B (en) Immunogenic composition against influenza
BR112015022095A8 (en) pharmaceutical composition, method of manufacture, eutectic composition and use of compositions containing hcl cyclobenzabrine and mannitol
CN108026053A8 (en) Condensed glyoxaline compound as mIDH1 inhibitor
HK1247856A1 (en) Hydroxypropyl beta-cyclodextrin compositions and methods
WO2014131739A3 (en) Substituted imidazopyridazines
WO2015033302A3 (en) Fulvestrant compositions
BR112014020930A2 (en) method for producing a dry formulation of a biopharmaceutical agent, and, formulation of a biopharmaceutical agent
WO2011140595A3 (en) Immunostimulatory and vaccine compositions
BR112017009510A2 (en) compositions comprising cyclosporine

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16728216

Country of ref document: EP

Kind code of ref document: A2

REEP Request for entry into the european phase

Ref document number: 2016728216

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE